Alpha 2.0
Login Register
» Authors » Jonathan Polikoff

Jonathan Polikoff

Explore the profile of Jonathan Polikoff including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 4514
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
Louis Fehrenbacher
Charles E Geyer Jr
Norman Wolmark
Sandra M Swain
Priya Rastogi
Eleftherios P Mamounas
Louise Provencher
James N Atkins
Adam M Brufsky
Andre Robidoux
Published In
J Clin Oncol
Breast Cancer Res Treat
Arch Surg
N Engl J Med
Lancet
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Geyer Jr C, Bandos H, Rastogi P, Jacobs S, Robidoux A, Fehrenbacher L, et al.
Breast Cancer Res Treat . 2022 May; 193(3):565. PMID: 35507135
No abstract available.
2.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Geyer Jr C, Bandos H, Rastogi P, Jacobs S, Robidoux A, Fehrenbacher L, et al.
Breast Cancer Res Treat . 2022 Mar; 193(3):555-564. PMID: 35230585
Purpose: Results from adjuvant trials evaluating 6 cycles of epirubicin-based chemotherapy regimens suggested these programs may be more effective than 4 cycles of doxorubicin-based chemotherapy. Method: NSABP B-36 was a...
3.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer
Ganz P, Bandos H, Geyer Jr C, Robidoux A, Paterson A, Polikoff J, et al.
Breast Cancer Res Treat . 2022 Feb; 192(1):153-161. PMID: 35112166
Background: The NSABP B-36 compared four cycles of doxorubicin and cyclophosphamide (AC) with six cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC-100) in node-negative early-stage breast cancer. A sub-study within B-36,...
4.
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2
Fehrenbacher L, Cecchini R, Geyer Jr C, Rastogi P, Costantino J, Atkins J, et al.
J Clin Oncol . 2019 Dec; 38(5):444-453. PMID: 31821109
Purpose: Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials...
5.
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by...
Ganz P, Romond E, Cecchini R, Rastogi P, Geyer Jr C, Swain S, et al.
J Clin Oncol . 2017 Oct; 35(35):3942-3948. PMID: 29072977
Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and health-related quality of life are lacking in long-term follow-up of...
6.
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Beer T, Kwon E, Drake C, Fizazi K, Logothetis C, Gravis G, et al.
J Clin Oncol . 2016 Dec; 35(1):40-47. PMID: 28034081
Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant prostate cancer...
7.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al.
Lancet . 2016 Dec; 389(10066):255-265. PMID: 27979383
Background: Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy...
8.
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Smith M, de Bono J, Sternberg C, Moulec S, Oudard S, De Giorgi U, et al.
J Clin Oncol . 2016 Jul; 34(25):3005-13. PMID: 27400947
Purpose: Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, and has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). This...
9.
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
Johnson B, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, et al.
J Clin Oncol . 2013 Oct; 31(31):3926-34. PMID: 24101054
Purpose: This phase III trial was performed to assess the potential benefit of adding maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced non-small-cell lung cancer...
10.
Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades
Haque R, Ahmed S, Inzhakova G, Shi J, Avila C, Polikoff J, et al.
Cancer Epidemiol Biomarkers Prev . 2012 Sep; 21(10):1848-55. PMID: 22989461
Background: We investigated the impact of breast cancer molecular subtypes and treatment on survival in a cohort of medically insured women followed for more than 20 years. Methods: We examined...